Loading...
Immunovia AB (publ)
0G8X.L•LSE
HealthcareMedical - Diagnostics & Research
$0.42
$0.02(5.72%)
Immunovia AB (publ) (0G8X.L) Stock Overview
Explore Immunovia AB (publ)’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
-40.89%
↓ 40.89%
Profit Growth
$-0.45
↑ 75.26%
EPS Growth
$-0.45
↑ 88.30%
Operating Margin
-11751.99%
↑ 63.09%
ROE
-269.40%
↑ 75.26%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 0G8X.LAnalyst Recommendations details for 0G8X.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
CEO
Mr. Jeff Borcherding
Employees
9
Headquarters
Medicon Village, Lund
Founded
2018